CalPERS Applauds CVS Caremark's Tobacco Exit
NEW YORK (TheStreet) - The California Public Employees Retirement System (CalPERS) said on Wednesday evening it applauded drugstore chain CVS Caremark's
"We applaud the decision by CVS to take this bold step and end its sale of tobacco products," CalPERS said in a statement. "The health of our members and their families is a top priority for our organization and clearly the use of tobacco is a key driver in the costs of health care. CVS' leadership helps promote a culture of wellness and health in our communities across the nation."
CalPERS is an important investor in CVS Caremark, and the first major fund to publicly support CVS Caremark's landmark decision. The fund held about 3.38 million CVS Caremark shares as of the third-quarter of 2013, worth about $221 million according to Wednesday closing share prices.
CVS Caremark shares fell just over 1% on Wednesday after announcing its decision to stop selling tobacco products by the start of the third quarter of 2014.
The move by CVS Caremark raises interesting questions about corporate governance and socially responsible investment that may gain further notice if other large CVS investors also take a stand.
Short-Term vs. Long-Term
CVS's decision could have a negative short-term impact on the company's earnings. However, the decision to end tobacco sales could also have a positive long-term impact on the company's positioning in the pharmacy business, especially as it works to launch new healthcare services in coming years.
TheStreet's Nicole Urken said in a Wednesday evening analysis that CVS's closer ties to healthy living categories could benefit long-term shareholders. Strong performing supermarkets and restaurants such as Whole Foods Market
It's also important to remember what CVS does.
The company is one of the biggest pharmacy networks in the world and it's stores sell drinks, snacks and other non-perishable foods that one might buy in a supermarket. Nevertheless, the company's biggest recent investments are in the healthcare space. CVS acquired pharmacy-benefit-manager (PBM) Caremark in 2007, building a hybrid retail-PBM business model.
Now, the company is investing heavily in a nationwide network of so-called MinuteClinics that may be a low-cost alternative to some doctor visits.
In that sense, CVS, above other competitors, appears to be the pharmacy with the biggest investment in healthcare and thus the greatest economic reason to end its sale of tobacco. Consumer perceptions are likely to be a big aspect of whether or not CVS can succeed in its healthcare investment, or not.
CVS also said its move would impact 2014 earnings guidance by 6 to 9cents per share, but the company "has identified incremental opportunities that are expected to offset the profitability impact." No change was made to its five-year financial projections.
From a short-term perspective, CVS's decision could lower the company's earnings by a few pennies. CVS said on Wednesday that ending tobacco sales may cause the company to lose $2 billion in annual revenue, or approximately 17 cents a share.
"Ending the sale of cigarettes and tobacco products at CVS/pharmacy is the right thing for us to do for our customers and our company to help people on their path to better health," Larry J. Merlo, CEO of CVS Caremark said in a statement. "Put simply, the sale of tobacco products is inconsistent with our purpose," he added.